microRNA-7 inhibition protects human osteoblasts from dexamethasone via activation of epidermal growth factor...

Area of Science:

• Molecular Biology
• Cell Biology
• Bone Biology

Background:

• Sustained dexamethasone (Dex) treatment can lead to secondary osteoporosis and bone fractures.
• Dex induces cytotoxicity in human osteoblasts, posing a risk to bone health.

Purpose of the Study:

• To investigate the role of microRNA-7 (miR-7) in dexamethasone-treated human osteoblasts.
• To determine if miR-7 targeting of epidermal growth factor receptor (EGFR) influences Dex-induced osteoblast toxicity.

Main Methods:

• Utilized lentiviral constructs for miR-7 depletion (LV-antagomiR-7) and overexpression (LV-miR-7) in human osteoblast cell lines (OB-6, hFOB1.19, primary cells).
• Assessed EGFR expression, Akt activation, cell viability, apoptosis, and luciferase activity of the EGFR 3-untranslated region.
• Employed EGFR inhibitors (AG1478, PD153035) and EGFR-knockout (EGFR-KO) cells to confirm the mechanism.
• Analyzed miR-7 and EGFR expression in necrotic femoral head tissues from Dex-administered patients.

Main Results:

• miR-7 depletion increased EGFR expression and Akt activation, protecting osteoblasts from Dex-induced cytotoxicity and apoptosis.
• miR-7 overexpression decreased EGFR expression and Akt activation, potentiating Dex-induced osteoblast toxicity.
• EGFR was confirmed as the primary target of miR-7 in osteoblasts, with functional studies validating the miR-7/EGFR signaling pathway.
• miR-7 was upregulated, and EGFR downregulated in necrotic bone tissues from patients treated with Dex.

Conclusions:

• miR-7 inhibition protects human osteoblasts from Dex-induced damage by activating the EGFR signaling pathway.
• The miR-7/EGFR axis represents a potential therapeutic target for mitigating Dex-induced bone toxicity.
• Findings elucidate a novel mechanism underlying Dex-induced osteoblast dysfunction and provide a basis for future therapeutic strategies.